Metabolically Healthy Obesity in Pediatric Population
1 other identifier
observational
100
0 countries
N/A
Brief Summary
The global epidemic of childhood obesity, with the accompanying rise in the prevalence of endocrine, metabolic, and cardiovascular comorbidities in youth, represents one of the most important public health issues of the modern world. Nevertheless, a distinct subgroup of youth with obesity less prone to the development of metabolic disturbances, called "metabolically healthy obese" (MHO), has come into focus. Defining the MHO subpopulation within the youth with obesity is of high importance in order to elucidate the mechanisms protecting against the clustering of cardiometabolic risk factors, and for its clinical, preventive, and therapeutic decision-making implications. Little is known about the mechanisms of development of metabolic disturbance in pediatric obesity. Cardiac autonomic function, which can be measured non-invasively with heart rate variability (HRV), has been suggested as a potential mechanism underlying the development of metabolic syndrome and cardiovascular disease. The aims of the present study were to investigate clinical, anthropometric, and socio-demographic and lifestyle predictors of MHO in this group and to asses correlation between HRV and the metabolic syndrome progression or improvement , in order to reveal if HRV can serve as a predictor to metabolic disturbance in pediatric obesity population Materials and Methods The study will be performed in the Nutrition and Obesity Clinic of the Pediatric Gastroenterology Unit at "Dana Dwek" Children's Hospital. All children and adolescents that that will be admitted to our clinic between January 2021 to December 2022 will include in the study. sociodemographic parameters will be collected from the medical files.Blood will be drawn for complete metabolic assesment. MUO children will be defined according to the recent international definition. Resting HRV will be measured by Pulse Oximeter (BM2000A/Shanghai Berry Electronic Tech Co., Ltd.). The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 31, 2020
CompletedFirst Posted
Study publicly available on registry
January 5, 2021
CompletedStudy Start
First participant enrolled
January 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2022
CompletedJanuary 5, 2021
January 1, 2021
1 year
December 31, 2020
January 4, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
prevalnce of metabolic disorder in obese pediatric population
measurment of glucose , insulin and lipid profile in all th chorot
2 years
Secondary Outcomes (1)
heart rate variability
2 years
Study Arms (2)
metabolic healthy obese
Demographic, clinical laboratory and heart rate variability assesment
metabolic unhealthy obese
Demographic, clinical laboratory and heart rate variability assesment
Interventions
Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months. HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points.
Eligibility Criteria
The study will be performed in the Nutrition and Obesity Clinic of the Pediatric Gastroenterology Unit at "Dana Dwek" Children's Hospital. All children and adolesecnt that that will be admitted to our clinic between December 2020 to December 2022 will include in the study.
You may qualify if:
- All children 10-18 with obesity, males and females, who attend the obesity clinic in the pediatric gastroenterology unit at "Dana-Dwek" children's hospital, Tel Aviv Sourasky Medical Center, will be included
You may not qualify if:
- Children with conditions that may affect HRV (e.g. congenital or acquired heart disease, other inflammatory conditions) will be excluded.
- withdrawal criteria: children and parents that will refuse to participate in the telephone interview will withdrawl from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
1. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes. (2006) 1:11-25. doi: 10.1080/1747 2. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. (2007) 8:299-306. doi: 10.1111/j.1399-5448.2007. 00271.x 3. Bluher S, Schwarz P. Metabolically healthy obesity from childhood to adulthood - does weight status alone matter?Metabolism. (2014) 63:1084-92 4. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes. (2011) 35:971-81. doi: 10.1038/ijo.2010.216 5. Weiss R, Taksali SE, Dufour S, Yeckel CW, Papademetris X, Cline G, et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. (2005) 90:3731-7. doi: 10.1210/jc.2004-2305 6. Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008 372:1281-3. doi: 10.1016/S0140-6736(08)61531-7 7. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. (2004) 89:2569-75. 8. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. (2001) 50:1499-504. 9. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. (2010) 21:38-43. 10. Damanhoury S, Newton AS, Rashid M, Hartling L, Byrne JLS, Ball GDC. Defining metabolically healthy obesity in children: a scoping review. Obes Rev. (2018) 19:1476-91 11. Vukovic R, Milenkovic T, Mitrovic K, Todorovic S, Plavsic L, Vukovic A, et al. Preserved insulin sensitivity predicts metabolically healthy obese phenotype in children and adolescents. Eur J Pediatr. (2015) 174:1649-55. 12. KiessW, PenkeM, Sergeyev E, NeefM, AdlerM, Gausche R, et al. Childhood obesity at the crossroads. J Pediatr Endocrinol Metab. (2015) 28:481-4. 13. Chen F, Liu J, Yan Y, Mi J, China Child and Adolescent Cardiovascular Health (CCACH) Study Group. Adolescent cardiovascular health study group. abnormal metabolic phenotypes among urban chinese children: epidemiology and the impact of DXA-measured body composition. Obesity. (2019) 27:837-44 14. Nasreddine L, Tamim H, Mailhac A, AlBuhairan FS. Prevalence and predictors of metabolically healthy obesity in adolescents: findings from the national "Jeeluna" study in Saudi-Arabia. BMC Pediatr. (2018) 18:281. 15. Roberge JB, Van Hulst A, Barnett TA, Drapeau V, Benedetti A, Tremblay A, et al. Lifestyle habits, dietary factors, and the metabolically unhealthy obese phenotype in youth. J Pediatr. (2019) 204:46-52. 16. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 2010; 141(2): 122-131. 17.Liao D, Cai J, Rosamond WD, et al. Cardiac autonomic function and incident coronary heart disease: A populationbased case-cohort study. The ARIC study. Atherosclerosis risk in communities study. Am J Epidemiol 1997; 145(8): 696-706 18. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: The atherosclerosis risk in communities study, 1987-1998. Circulation 2003; 107(17): 2190-2195. 19. Carnethon MR, Prineas RJ, Temprosa M, et al. The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program. Diabetes Care 2006; 29(4): 914-919 20.La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial infarction) investigators. Lancet 1998; 351(9101): 478-484
BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
shlomi cohen, md
pediatric gastroenterology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
December 31, 2020
First Posted
January 5, 2021
Study Start
January 15, 2021
Primary Completion
January 15, 2022
Study Completion
January 30, 2022
Last Updated
January 5, 2021
Record last verified: 2021-01
Data Sharing
- IPD Sharing
- Will not share
Information about study subjects will remain confidential and will be managed according to the GCP requirements. The study involves de-identified data extracted from medical records. Irreversible anonymization (where it is impossible or extremely difficult to go back and uncover the identity of the patient) will be performed either by the principal investigator or by sub-investigator that has clearance to open medical records. The data file will not be sent by un-encrypted email and will not be transferred outside the medical center without prior approval on a signed data transfer agreement with the R\&D department.